Related Experiment Video

Updated: Jan 25, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian

Sergei Krasny1, Yauheni Baranau2, Evgeny Bakin3

  • 1N. N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|January 23, 2026
PubMed
Abstract

Insights

Adding Elenagen to gemcitabine significantly improved overall survival for patients with platinum-resistant ovarian cancer. This novel plasmid DNA therapy demonstrated enhanced efficacy without increasing toxicity, offering a promising new treatment option.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Platinum-resistant ovarian cancer presents a significant therapeutic challenge with limited effective treatments.
  • Elenagen, a plasmid DNA-based agent encoding p62/SQSTM1, targets selective autophagy and signal transduction.
  • Previous studies reported progression-free survival outcomes for Elenagen in this patient population.

Purpose of the Study:

  • To evaluate the overall survival results of a phase II randomized controlled trial comparing Elenagen plus gemcitabine versus gemcitabine alone.
  • To assess the safety and efficacy of Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer.

Main Methods:

  • An open-label, prospective, randomized, 2-center study enrolled women with platinum-resistant ovarian cancer.
  • Patients were randomized (1:1) to receive gemcitabine monotherapy or gemcitabine plus Elenagen (2.5 mg IM weekly).
  • Overall survival was the primary endpoint, analyzed using Kaplan-Meier and Cox proportional hazards models.

Main Results:

  • Median overall survival was 25 months (Elenagen + gemcitabine) vs. 13 months (gemcitabine alone) in patients with elevated CA-125 levels (p = .031).
  • Elenagen addition showed a 59% reduction in the risk of death (HR 0.41, p = .036).
  • No additional safety concerns were identified with Elenagen combination therapy.

Conclusions:

  • The combination of Elenagen and gemcitabine significantly prolonged overall survival in patients with platinum-resistant ovarian cancer.
  • Elenagen represents a safe and effective therapeutic option, enhancing gemcitabine's efficacy without increasing toxicity.
Keywords:
ElenagenGemcitabinePlasmid TherapyPlatinum-Resistant Ovarian Cancerp62/SQSTM1

More Related Videos

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.0K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

2.2K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
658
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Encoding01:19

Encoding

Information enters the brain through encoding, which is the input of information into the memory system. Once sensory information is received from the environment, the brain labels or codes it. The information is then organized with similar information and connected to existing concepts. Encoding occurs through automatic processing and effortful processing.
Automatic processing involves the encoding of details like time, space, frequency, and the meaning of words, usually done without conscious...
777
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Plasmids01:28

Plasmids

Plasmids are extrachromosomal DNA molecules found in bacteria, archaea, and some eukaryotic microbes like yeast. These small, circular DNA structures typically contain fewer than 30 genes, although some may exist linearly. Plasmids vary in their number within a cell, known as copy number. Single-copy plasmids are present in one copy per cell and multi-copy plasmids are present in multiple copies, reaching over 100 copies per cell.Plasmids usually replicate independently of the chromosomal DNA...
1.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K